Genmab — April 2018
-
that would be awesome. "Sellside consensus compiled by EvaluatePharma shows 2022 revenue of $572m for OMB157 versus a still optimistic $267m for Arzerra, and Leerink reckons ofatumumab’s MS incarnation could be generating blockbuster sales by 2026." http://www.epvantage.com/Universal/View.aspx?type=Story&id=740722&isEPVantage=yes
-
Okay, lavt 2-cifret måske 12-15% https://finans.dk/erhverv/ECE9788226/genmab-kan-score-ny-milliardjackpot/?ctxref=ext
-
Apropos morgenens udveksling om ADCT, så var der jo faktisk indirekte indbygget en god nyhed om ADCT-301, da de udtaler, at "He also points to the progress being made with ADCT’s two lead candidates that are still firmly on course to start later-stage testing before the end of the year. "
-
-
Kan vi være sikker på at ADCT-301 er et af disse lead candidates? De kan vel have andre?
-
Abstract fra amr. producent af actinium: https://www.ncbi.nlm.nih.gov/pubmed/15763472
-
GB: den står øverst på listen og er længst fremme sammen med -402 http://adctherapeutics.com/
-
Actimium forhøjes daras potens med 10 gange! Er det så ikke knock out til Revlimid og Velcade? Eller er de stadig nødvendige?
-
forhøjes = forhøjer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind